A widely publicised Cochrane review published on April 16, 2026, casts doubt on the clinical value of amyloid β-targeting monoclonal antibodies for Alzheimer's disease. The meta-analysis, aggregating data from 17 randomised trials with more than 20,000 participants, found these therapies likely result in little to no difference in cognitive function or dementia severity.
The review chips away at the amyloid hypothesis, a decades-old theory positing that amyloid plaques drive neurodegeneration. While the drugs showed small improvements in functional ability, those gains were overshadowed by a lack of meaningful cognitive benefit, reigniting debate over the hypothesis itself.
Safety data revealed small increases in side-effects, particularly amyloid-related imaging abnormalities indicating oedema or effusions (ARIA-E). However, the analysis found little or no difference in serious adverse events or death rates between treatment and placebo groups.
For patients and clinicians, the findings suggest limited therapeutic upside from current anti-amyloid antibodies outside of modest functional effects. The implications could steer research toward alternative disease mechanisms, such as tau pathology or neuroinflammation, and away from amyloid-centric approaches.
The Cochrane authors caution that the included trials varied in drug type, dosing, and outcome measures, which may have masked subgroup differences. Critics of the analysis argue it may overgeneralize results across a diverse class of agents.